Trial
NCT04450654
Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Washington
Collaborators
Grifols Biologicals, LLC
Condition
Immune-Mediated Necrotizing Myopathy
Intervention
Gamunex-C
Why stopped
No Participants Enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-10-24